Interactions between misfolded protein oligomers and membranes: A central topic in neurodegenerative diseases?

Biochimica et Biophysica Acta - Biomembranes

Volumn 1848, Issue 9, 2015, Pages 1897-1907

  Andreasen, Maria ^a,b   Lorenzen, Nikolai ^c   Otzen, Daniel ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Alpha synuclein; Amyloid; Anionic lipids; Fasciclin domain; Membrane destabilization; Protein oligomer

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; DRONABINOL; EPIGALLOCATECHIN GALLATE; FASCICLIN I; MONOMER; OLIGOMER; PEPTIDOMIMETIC AGENT; PROTEIN FAS1-4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED PROTEIN; UNCLASSIFIED DRUG; MEMBRANE LIPID; MEMBRANE PROTEIN; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ARTICLE; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG BINDING; HUMAN; HYDROPHOBICITY; IMMUNOTHERAPY; IN VIVO STUDY; LIPID MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; ANIMAL; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN MULTIMERIZATION;

ANIMALS; CELL MEMBRANE; HUMANS; MEMBRANE LIPIDS; MEMBRANE PROTEINS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN MULTIMERIZATION;

EID: 84936892251     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2015.01.018     Document Type: Review

References (140)

1. F. Chiti, and C.M. Dobson Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366
2. G.M. Hirschfield, and P.N. Hawkins Amyloidosis: new strategies for treatment Int. J. Biochem. Cell Biol. 35 12 2003 1608 1613
3. A.T. Alexandrescu Amyloid accomplices and enforcers Protein Sci. 14 1 2005 1 12
4. M. Stefani Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world Biochim. Biophys. Acta 1739 1 2004 5 25
5. M. Stefani, and C.M. Dobson Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution J. Mol. Med. (Berl) 81 11 2003 678 699
6. C.M. Dobson Protein aggregation and its consequences for human disease Protein Pept. Lett. 13 3 2006 219 227
7. E.D. Eanes, and G.G. Glenner X-ray diffraction studies on amyloid filaments J. Histochem. Cytochem. 16 11 1968 673 677
8. L.C. Serpell, P.E. Fraser, and M. Sunde X-ray fiber diffraction of amyloid fibrils Methods Enzymol. 309 1999 526 536
9. R. Nelson, and D. Eisenberg Structural models of amyloid-like fibrils Adv. Protein Chem. 73 2006 235 282
10. J.D. Sipe, and A.S. Cohen Review: history of the amyloid fibril J. Struct. Biol. 130 2-3 2000 88 98
11. T.P.J. Knowles Spatial persistence of angular correlations in amyloid fibrils Phys. Rev. Lett. 96 2006 238301
12. L.C. Serpell The protofilament substructure of amyloid fibrils J. Mol. Biol. 300 5 2000 1033 1039
13. J.-X. Lu Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue Cell 154 6 2013 1257 1268
14. C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 9 1999 329 332
15. K.F. DuBay Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains J. Mol. Biol. 341 5 2004 1317 1326
16. F. Chiti Rationalization of the effects of mutations on peptide and protein aggregation rates Nature 424 6950 2003 805 808
17. S.K. Maji Functional amyloids as natural storage of peptide hormones in pituitary secretory granules Science 325 5938 2009 328 332
18. J.F. Berson Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis J. Cell Biol. 161 3 2003 521 533
19. J.A. Hardy, and G.A. Higgins Alzheimer's disease: the amyloid cascade hypothesis Science 256 5054 1992 184 185
20. D.W. Dickson Identification of normal and pathological aging in prospectively studied nondemented elderly humans Neurobiol. Aging 13 1 1992 179 189
21. R.D. Terry Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30 4 1991 572 580
22. C.A. Lemere Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol. Dis. 3 1 1996 16 32
23. D.W. Dickson Correlations of synaptic and pathological markers with cognition of the elderly Neurobiol. Aging 16 3 1995 285 298 (discussion 298-304)
24. B. Caughey, and P.T. Lansbury Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26 2003 267 298
25. M.J. Volles, and P.T. Lansbury Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease Biochemistry 42 26 2003 7871 7878
26. K.E. Paleologou Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies Brain 132 Pt 4 2009 1093 1101
27. T. Tokuda Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease Neurology 75 20 2010 1766 1772
28. M. Bucciantini Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 6880 2002 507 511
29. I. Sirangelo Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F J. Biol. Chem. 279 13 2004 13183 13189
30. W. Paslawski High stability and cooperative unfolding of alpha-synuclein oligomers Biochemistry 53 39 2014 6252 6263
31. A. Quist Amyloid ion channels: a common structural link for protein-misfolding disease Proc. Natl. Acad. Sci. U. S. A. 102 30 2005 10427 10432
32. R. Kayed Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 5618 2003 486 489
33. N. Lorenzen The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation J. Am. Chem. Soc. 136 10 2014 3859 3868
34. W. Paslawski Co-existence of two different alpha-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass spectrometry Angew. Chem. Int. Ed. Engl. 53 29 2014 7560 7563
35. A.T. Petkova Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils Science 307 5707 2005 262 265
36. K. Yamaguchi Seeding-dependent propagation and maturation of amyloid fibril conformation J. Mol. Biol. 352 4 2005 952 960
37. C.J. Cummings Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1 Nat. Genet. 19 2 1998 148 154
38. K. Ii Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly J. Neuropathol. Exp. Neurol. 56 2 1997 125 131
39. C. Soto Unfolding the role of protein misfolding in neurodegenerative diseases Nat. Rev. Neurosci. 4 1 2003 49 60
40. C. Behl Hydrogen peroxide mediates amyloid beta protein toxicity Cell 77 6 1994 817 827
41. L.J. Hsu Alpha-synuclein promotes mitochondrial deficit and oxidative stress Am. J. Pathol. 157 2 2000 401 410
42. P. Jenner, and C.W. Olanow Understanding cell death in Parkinson's disease Ann. Neurol. 44 3 Suppl 1 1998 S72 S84
43. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S26 S36 (discussion S36-8)
44. B.J. Tabner Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases Curr. Top. Med. Chem. 1 6 2001 507 517
45. M.S. Parihar Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells Int. J. Biochem. Cell Biol. 41 10 2009 2015 2024
46. N. Lorenzen The N-terminus of alpha-synuclein is essential for both monomeric and oligomeric interactions with membranes FEBS Lett. 588 3 2014 497 502
47. N. Lorenzen How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro J. Biol. Chem. 289 31 2014 21299 21310
48. A.N. Stefanovic Alpha-synuclein oligomers distinctively permeabilize complex model membranes FEBS J. 281 12 2014 2838 2850
49. C.M. van Rooijen BD, and V. Subramaniam Membrane permeabilization by oligomeric α-synuclein: in search of the mechanism PLoS ONE 5 2010
50. M.J. Volles, and P.T. Lansbury Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity J. Mol. Biol. 366 5 2007 1510 1522
51. B.D. van Rooijen Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers J. Mol. Biol. 394 5 2009 826 833
52. M.J. Volles, S.-J. Lee, J.-C. Rochet, M.D. Shtilerman, T.T. Ding, J.C. Kessler, and P.T. Lansbury Vesicle Permeabilization by Protofibrillar α-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's Disease Biochemistry 40 26 2001 7812 7819
53. M. Stockl, M.M. Claessens, and V. Subramaniam Kinetic measurements give new insights into lipid membrane permeabilization by alpha-synuclein oligomers Mol. BioSyst. 8 1 2012 338 345
54. B.D. van Rooijen, M.M. Claessens, and V. Subramaniam Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core Biochim. Biophys. Acta 1788 6 2009 1271 1278
55. E. Sparr Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers FEBS Lett. 577 1-2 2004 117 120
56. N. Arispe, E. Rojas, and H.B. Pollard Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum Proc. Natl. Acad. Sci. 90 2 1993 567
57. M.C. Lin, T. Mirzabekov, and B.L. Kagan Channel formation by a neurotoxic prion protein fragment J. Biol. Chem. 272 1 1997 44 47
58. T.A. Mirzabekov, M. Lin, and B.L. Kagan Pore formation by the cytotoxic islet amyloid peptide amylin J. Biol. Chem. 271 4 1996 1988
59. M. Andreasen Polymorphic fibrillation of the destabilized fourth fasciclin-1 domain mutant A546T of the transforming growth factor-β-induced protein (TGFBIp) occurs through multiple pathways with different oligomeric intermediates J. Biol. Chem. 287 41 2012 34730 34742
60. L. Pieri The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state J. Biol. Chem. 281 22 2006 15337 15344
61. S. Campioni A causative link between the structure of aberrant protein oligomers and their toxicity Nat. Chem. Biol. 6 2 2010 140 147
62. M. Stefani Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity Neuroscientist 13 5 2007 519 531
63. I. Kheterpal, and R. Wetzel Hydrogen/deuterium exchange mass spectrometry - a window into amyloid structure Acc. Chem. Res. 39 9 2006 584 593
64. N. Cremades Direct observation of the interconversion of normal and toxic forms of alpha-synuclein Cell 149 5 2012 1048 1059
65. M.H. Polymeropoulos Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 5321 1997 2045 2047
66. M.G. Spillantini Alpha-synuclein in Lewy bodies Nature 388 6645 1997 839 840
67. M.M. Dedmon Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations J. Am. Chem. Soc. 127 2 2005 476 477
68. J.R. Allison Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements J. Am. Chem. Soc. 131 51 2009 18314 18326
69. C. Del Mar Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level Proc. Natl. Acad. Sci. U. S. A. 102 43 2005 15477 15482
70. S. Mysling Characterizing the dynamics of alpha-synuclein oligomers using hydrogen/deuterium exchange monitored by mass spectrometry Biochemistry 52 51 2013 9097 9103
71. W.S. Davidson Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes J. Biol. Chem. 273 16 1998 9443 9449
72. T.S. Ulmer Structure and dynamics of micelle-bound human alpha-synuclein J. Biol. Chem. 280 10 2005 9595 9603
73. C.R. Bodner Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy Biochemistry 49 5 2010 862 871
74. T. Bartels The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding Biophys. J. 99 7 2010 2116 2124
75. G. Fusco Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour Nat. Commun. 5 2014 3827
76. J. Varkey Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins J. Biol. Chem. 285 42 2010 32486 32493
77. M.B. Jensen Membrane curvature sensing by amphipathic helices: a single liposome study using alpha-synuclein and annexin B12 J. Biol. Chem. 286 49 2011 42603 42614
78. M.M. Ouberai Alpha-synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling J. Biol. Chem. 288 29 2013 20883 20895
79. M.J. Volles, and P.T. Lansbury Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism Biochemistry 41 14 2002 4595 4602
80. H.A. Lashuel Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 6895 2002 291
81. N. Zijlstra Molecular composition of sub-stoichiometrically labeled alpha-synuclein oligomers determined by single-molecule photobleaching Angew. Chem. Int. Ed. Engl. 51 35 2012 8821 8824
82. L. Giehm, S.D., D.E. Otzen, and B. Vestergaard Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation Proc. Natl. Acad. Sci. U. S. A. 108 8 2011 3246 3251
83. J.I. Gallea, and M.S. Celej Structural insights into amyloid oligomers of the Parkinson disease-related protein alpha-synuclein J. Biol. Chem. 289 39 2014 26733 26742
84. M.S. Celej Toxic prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet structure Biochem. J. 443 3 2012 719 726
85. W. Paslawski, N. Lorenzen, and D.E. Otzen Formation and characterization of α-synuclein oligomers Methods Mol. Biol. 2015 (in press)
86. L. Kjaer The influence of vesicle size and composition on alpha-synuclein structure and stability Biophys. J. 96 7 2009 2857 2870
87. B.D. van Rooijen, M.M. Claessens, and V. Subramaniam Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing FEBS Lett. 582 27 2008 3788 3792
88. B. Bolognesi ANS binding reveals common features of cytotoxic amyloid species ACS Chem. Biol. 5 8 2010 735 740
89. K. Vamcava, M.J. Volles, and P.T. Lansbury The first N-terminal amino acids of α-synuclein are essential for α-helical structure formation in vitro and membrane binding in yeast J. Mol. Biol. 389 4755 2009 413 424
90. K. Runager Human phenotypically distinct TGFBI corneal dystrophies are linked to the stability of the fourth FAS1 domain of TGFBIp J. Biol. Chem. 286 7 2011 4951 4958
91. F.L. Munier Kerato-epithelin mutations in four 5q31-linked corneal dystrophies Nat. Genet. 15 3 1997 247 251
92. C. Kannabiran, and G.K. Klintworth TGFBI gene mutations in corneal dystrophies Hum. Mutat. 27 7 2006 615 625
93. G.K. Klintworth The molecular genetics of the corneal dystrophies - current status Front. Biosci. 8 2003 d687 d713
94. J. Skonier cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta DNA Cell Biol. 11 7 1992 511 522
95. B.W. Streeten Immunolocalization of beta ig-h3 protein in 5q31-linked corneal dystrophies and normal corneas Arch. Ophthalmol. 117 1 1999 67 75
96. E. Korvatska Amyloid and non-amyloid forms of 5q31-linked corneal dystrophy resulting from kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein J. Biol. Chem. 275 15 2000 11465 11469
97. E. Korvatska Mutation hot spots in 5q31-linked corneal dystrophies Am. J. Hum. Genet. 62 2 1998 320 324
98. P. Dighiero A new mutation (A546T) of the betaig-h3 gene responsible for a French lattice corneal dystrophy type IIIA Am J. Ophthalmol. 129 2 2000 248 251
99. R.V. Basaiawmoit SAXS models of TGFBIp reveal a trimeric structure and show that the overall shape is not affected by the Arg124His mutation J. Mol. Biol. 408 3 2011 503 513
100. D.C. Beebe Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues Semin. Cell Dev. Biol. 19 2 2008 125 133
101. H. Karring Composition and proteolytic processing of corneal deposits associated with mutations in the TGFBI gene Exp. Eye Res. 96 1 2012 163 170
102. R.B. Andersen Purification and structural characterization of transforming growth factor beta induced protein (TGFBIp) from porcine and human corneas Biochemistry 43 51 2004 16374 16384
103. B. Solomon Disaggregation of Alzheimer beta-amyloid by site-directed mAb Proc. Natl. Acad. Sci. U. S. A. 94 8 1997 4109 4112
104. C. Janus A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 6815 2000 979 982
105. C.A. Hawkes Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease Eur. J. Neurosci. 31 2 2010 203 213
106. K. Bodin Antibodies to human serum amyloid P component eliminate visceral amyloid deposits Nature 468 7320 2010 93 97
107. M. Botto Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene Nat. Med. 3 8 1997 855 859
108. A. Lorenzo, and B.A. Yankner Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red Proc. Natl. Acad. Sci. U. S. A. 91 25 1994 12243 12247
109. V. Heiser Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy Proc. Natl. Acad. Sci. U. S. A. 97 12 2000 6739 6744
110. W.E. Klunk Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells Life Sci. 63 20 1998 1807 1814
111. F. Yang Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 7 2005 5892 5901
112. F.E. Herrera Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region PLoS ONE 3 10 2008 e3394
113. E.H. Norris Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations J. Biol. Chem. 280 22 2005 21212 21219
114. J. Li Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J. 18 9 2004 962 964
115. S.L. Leong Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation Free Radic. Biol. Med. 46 10 2009 1328 1337
116. D.E. Ehrnhoefer EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15 6 2008 558 566
117. J. Bieschke EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc. Natl. Acad. Sci. U. S. A. 107 17 2010 7710 7715
118. C. Cao The potential therapeutic effects of THC on Alzheimer's disease J. Alzheimers Dis. 42 3 2014 973 984
119. O.M. El-Agnaf A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders FASEB J. 18 11 2004 1315 1317
120. K. Muthusamy Design and study of peptide-based inhibitors of amylin cytotoxicity Bioorg. Med. Chem. Lett. 20 4 2010 1360 1362
121. R. Shaltiel-Karyo Inhibiting alpha-synuclein oligomerization by stable cell-penetrating beta-synuclein fragments recovers phenotype of Parkinson's disease model flies PLoS ONE 5 11 2010 e13863
122. A.M. Bodles Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue Neurosci. Lett. 359 1-2 2004 89 93
123. B.M. Austen Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide Biochemistry 47 7 2008 1984 1992
124. C. Soto Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation Biochem. Biophys. Res. Commun. 226 3 1996 672 680
125. P. Hoogerhout A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid beta and elicits antibodies against oligomeric and fibrillar amyloid and plaques PLoS ONE 6 4 2011 e19110
126. A.A. Reinke Chemical probes that selectively recognize the earliest Abeta oligomers in complex mixtures J. Am. Chem. Soc. 132 50 2010 17655 17657
127. A.D. Williams Structural properties of Abeta protofibrils stabilized by a small molecule Proc. Natl. Acad. Sci. U. S. A. 102 20 2005 7115 7120
128. J. Bieschke Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils Nat. Chem. Biol. 8 1 2012 93 101
129. L. Bousset Structural and functional characterization of two alpha-synuclein strains Nat. Commun. 4 2013
130. M. Bucciantini Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1 FASEB J. 26 2 2012 818 831
131. J.D. Knight, and A.D. Miranker Phospholipid catalysis of diabetic amyloid assembly J. Mol. Biol. 341 5 2004 1175 1187
132. 2m-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH PLoS ONE 9 8 2014
133. L. Milanesi Direct three-dimensional visualization of membrane disruption by amyloid fibrils Proc. Natl. Acad. Sci. U. S. A. 109 50 2012 20455 20460
134. H. Zhao, E.K.J. Tuominen, and P.K.J. Kinnunen Formation of amyloid fibers triggered by phosphatidylserine-containing membranes Biochemistry 43 3610 2004 10302 10307
135. M.F. Engel Islet amyloid polypeptide inserts into phospholipid monolayers as monomer J. Mol. Biol. 356 3 2006 783 789
136. M.F. Sciacca Two-step mechanism of membrane disruption by Abeta through membrane fragmentation and pore formation Biophys. J. 103 4 2012 702 710
137. M.F. Engel Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane Proc. Natl. Acad. Sci. U. S. A. 105 16 2008 6033 6038
138. J.D. Knight, and A.D. Miranker Phospholipid catalysis of diabetic amyloid assembly J. Mol. Biol. 341 2004 1175 1187
139. A. Iyer Amyloids of alpha-synuclein affect the structure and dynamics of supported lipid bilayers Biophys. J. 106 12 2014 2585 2594
140. H. Chaudhary Membrane interactions and fibrillization of alpha-synuclein play an essential role in membrane disruption FEBS Lett. 588 23 2014 4457 4463